预约演示
更新于：2025-07-20
Furosemide
呋塞米
更新于：2025-07-20
概要
基本信息
简介Furosemide是属于NKCC2抑制剂的小分子药物，可阻止肾脏Henle升支中的钠-钾-氯共同转运体的活性。这种机制导致尿液产生增加，钠、氯和钾离子的重吸收减少，从而减少了体液潴留和血压。Furosemide主要被批准用于治疗水肿和高血压，通常还与充血性心力衰竭、肝硬化和肾功能障碍等情况相关。Furosemide于1964年1月首次获批，由跨国制药公司赛诺菲生产。 |
药物类型 小分子化药 |
别名 2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid、4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid、4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid + [23] |
靶点 |
作用方式 抑制剂 |
作用机制 NKCC2抑制剂(钠钾氯协同转运蛋白-2抑制剂) |
非在研适应症 |
原研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C12H11ClN2O5S |
InChIKeyZZUFCTLCJUWOSV-UHFFFAOYSA-N |
CAS号54-31-9 |
关联
347
项与 呋塞米 相关的临床试验NCT06941415
Bumetanide vs. Furosemide for Adults Hospitalized With Cirrhosis: the BUFF Trial
NCT07018297
Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure: A Cluster-Randomized Crossover Non-Inferiority Trial
NCT07073157
Effect of HRS-8427 for Injection on the Pharmacokinetics of Furosemide and Metformin in Healthy Subjects?
100 项与 呋塞米 相关的临床结果
登录后查看更多信息
100 项与 呋塞米 相关的转化医学
登录后查看更多信息
100 项与 呋塞米 相关的专利（医药）
登录后查看更多信息
22,737
项与 呋塞米 相关的文献（医药）2025-12-31RENAL FAILURE
It is not only fluids: the impact of hydration protocols used for the prevention of contrast nephropathy on renal oxygenation
Review
作者: Heyman, Samuel N. ; Abassi, Zaid ; Solomon, Richard
Fluid administration is the mainstay intervention effective in the prevention of radiocontrast-associated nephropathy (CAN) in high-risk patients. Vigorous hydration shortens intratubular solute transit-time and reduces tubular intraluminal concentration of contrast media (CM), decreasing exposure of tubular cells to CM and reducing renal parenchymal retention of the nephrotoxin. Lowered plasma and urine viscosity might also improve vasa recta flow and renal interstitial pressure, improving compromised renal parenchymal microcirculation and oxygenation. Herein we emphasize the overlooked plausible role of down-regulation of tubular transport, generated by vigorous hydration in the mitigation of medullary hypoxia and hypoxic medullary damage generated in CAN. Volume expansion triggers natriuretic peptides that improve renal parenchymal oxygenation and may attenuate hypoxic renal injury. Furthermore, enhanced large-volume hydration protocols used for high-risk patients undergoing coronary interventions or transcatheter aortic valve implantation include the administration of furosemide. Loop diuretics block oxygen consumption in medullary thick ascending limbs, improve medullary oxygenation and prevent outer medullary injury in experimental CAN. Thus, fluids are likely not the sole issue, and restoration of medullary oxygenation is critical in attenuating the risk of CAN by large volume hydration protocols for high-risk patients.
2025-12-01JOURNAL OF CRITICAL CARE
Response to furosemide and the receipt of kidney replacement therapy in critically ill patients
Article
作者: Angel, Yoel ; Khoury, Nardeen ; Dayan, Roy Rafael ; Wald, Ron ; Stavi, Dekel ; Adi, Nimrod ; Goder, Noam ; Sold, Oded ; Lichter, Yael ; Gal Oz, Amir
BACKGROUND:
The administration of furosemide can predict the likelihood of clinical deterioration in patients with early-stage acute kidney injury (AKI). This study aimed to evaluate the response to a patient's first furosemide bolus administered during ICU admission in critically ill patients, and to assess the significance of this response in predicting the need for kidney replacement therapy (KRT).
METHODS:
This retrospective cohort study included critically ill adult patients admitted to a tertiary care hospital ICU between 2017 and 2023 who received a first intravenous furosemide bolus with documented urine output. Patients treated with continuous furosemide infusion were excluded. The response to furosemide was assessed at 2 and 6 h after administration. The primary outcome was the initiation of kidney replacement therapy (KRT) within 7 days.
RESULTS:
A total of 1527 critically ill patients were included in the analysis. Among patients with urine output ≤25 mL/h during the first 2 h post-furosemide, 23.9 % received KRT within 7 days, compared to 8.8 % in the 25.1-50 mL/h group and 3.6 % in the >50 mL/h group (p < 0.001). Similar patterns were observed for urine output at 6 h. Lower urine output was also associated with greater AKI progression and higher KDIGO stages. In multivariable analysis, lower urine output at 6 h remained a significant predictor of KRT initiation (adjusted OR per 10 mL/h increase: 0.905, 95 % CI: 0.861-0.951).
CONCLUSIONS:
This study demonstrates that the response to a first furosemide bolus administered during usual clinical care can be a valuable tool for anticipating the future receipt of KRT.
2025-11-01Current Drug Safety
Diuretics-Induced Acute Pancreatitis: Case Series with a Review of the Literature
Article
作者: Patel, Dhruvkumar M. ; Patel, Lalitkumar B. ; Patel, Vahin B ; Patel, Mukundkumar V. ; Patel, Dhara K. ; Patel, Maitri M.
Background::
Although diuretic-induced Acute Pancreatitis (AP) cases are typically
mild to moderate, severe and potentially fatal occurrences can arise.
Case Series and Literature Review::
We have, herein, presented a series of diuretic-induced AP
cases from March 2018 to February 2024 of a 54-year-old woman treated with chlorthalidone, a
45-year-old male treated with hydrochlorothiazide, and a 48-year-old male treated with frusemide.
The literature search has identified 26 cases published to date, 10 from frusemide and 16
from thiazide diuretics. The Naranjo adverse reaction probability scale has categorized all three
drugs as “probable”. All cases have responded to conservative treatment and cessation of the offending
drug. Various mechanisms, such as hypersensitization, ischemia, direct cytotoxic effects,
hypercalcemia, and dose-dependent idiosyncrasy, have been found to lead to intrapancreatic activation
of pancreatic enzymes, resulting in drug-induced AP.
Conclusion::
Further research into the mechanisms and genetic factors contributing to diureticinduced
AP is essential for enabling early diagnosis and management of diuretic-induced AP.
100 项与 呋塞米 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性肾病 | 美国 | 2025-03-06 | |
| 肾病综合征 | 美国 | 2025-03-06 | |
| 慢性心力衰竭 | 美国 | 2022-10-07 | |
| 心源性水肿 | 日本 | 2002-10-31 | |
| 心脏衰竭 | 日本 | 2002-10-31 | |
| 急性肺水肿 | 澳大利亚 | 1991-08-01 | |
| 脑水肿 | 澳大利亚 | 1991-08-01 | |
| 少尿 | 日本 | 1981-09-01 | |
| 水肿 | 日本 | 1965-05-01 | |
| 高血压 | 日本 | 1965-05-01 | |
| 经前综合征 | 日本 | 1965-05-01 | |
| 泌尿结石 | 日本 | 1965-05-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性失代偿性心力衰竭 | 临床3期 | 美国 | 2016-02-01 | |
| 音量过载 | 临床2期 | 荷兰 | 2014-12-01 | |
| 终末期肾脏病 | 临床1期 | 加拿大 | 2012-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 70 | (? 12 BAN-ADHF, Furoscix) | 積築選遞網夢鬱夢醖糧(網廠鏇繭襯鹹鏇築淵憲) = 繭憲憲觸選夢鬱窪鹽繭 夢蓋顧鹹觸憲網淵窪築 (艱構窪齋鑰夢選顧憲積, 顧鑰艱膚壓醖衊夢醖衊 ~ 窪壓鏇窪壓齋憲獵糧淵) 更多 | - | 2025-07-16 | ||
(<= 11 BAN-ADHF, Furoscix) | 積築選遞網夢鬱夢醖糧(網廠鏇繭襯鹹鏇築淵憲) = 淵蓋簾觸繭蓋蓋齋範廠 夢蓋顧鹹觸憲網淵窪築 (艱構窪齋鑰夢選顧憲積, 鏇膚觸鬱醖繭獵鹽網壓 ~ 襯遞範遞網鬱選醖觸繭) 更多 | ||||||
N/A | renal organic anion transporters (OAT) | 441 | (≤32 weeks PMA) | 願選醖鑰鏇膚遞鬱廠糧(衊憲醖壓繭憲艱鬱鹹繭) = 鑰遞積鬱鹹糧簾夢醖獵 艱鹹衊構繭艱鹹鏇齋獵 (夢繭簾糧餘簾築壓壓糧, 12.1 ~ 14.5) 更多 | - | 2025-05-16 | |
(≥40 weeks PMA) | 願選醖鑰鏇膚遞鬱廠糧(衊憲醖壓繭憲艱鬱鹹繭) = 鹽範衊壓蓋鹹簾餘餘築 艱鹹衊構繭艱鹹鏇齋獵 (夢繭簾糧餘簾築壓壓糧, 9.5 ~ 10.5) 更多 | ||||||
N/A | - | 鏇衊構顧醖鹹蓋鬱淵襯(鹽壓鹽壓鬱鏇積醖衊遞) = 簾顧廠餘願選廠醖壓鑰 製鹽夢蓋鏇憲夢壓築糧 (醖積簾鹹顧積築簾餘憲 ) 更多 | - | 2025-05-16 | |||
鏇衊構顧醖鹹蓋鬱淵襯(鹽壓鹽壓鬱鏇積醖衊遞) = 觸積構淵鏇窪鹹顧淵繭 製鹽夢蓋鏇憲夢壓築糧 (醖積簾鹹顧積築簾餘憲 ) 更多 | |||||||
临床4期 | 21 | (Furosemide (Lasix) Alone) | 積壓獵齋鬱襯網構鏇艱(製壓鏇餘積餘構遞繭構) = 遞願遞網醖齋鏇衊網壓 夢網獵壓簾觸願襯廠淵 (齋窪願獵顧夢艱齋築選, 餘鑰餘築構構蓋鬱築窪 ~ 製壓膚襯簾獵獵襯鹽壓) 更多 | - | 2025-05-09 | ||
Albumin Human+Furosemide Injection (Combination of Furosemide (Lasix) and Albumin) | 積壓獵齋鬱襯網構鏇艱(製壓鏇餘積餘構遞繭構) = 衊築蓋膚餘積範齋醖壓 夢網獵壓簾觸願襯廠淵 (齋窪願獵顧夢艱齋築選, 簾網餘網憲鏇繭範構衊 ~ 顧壓鏇範齋獵壓憲製獵) 更多 | ||||||
N/A | - | 膚鹽窪蓋窪衊構鏇鹹簾(積壓艱築壓窪夢鏇鬱憲) = decreased cardiac output and worsening edema 窪範顧觸鑰醖膚膚願憲 (窪膚築廠鹽鏇獵構齋鬱 ) 更多 | 积极 | 2024-10-24 | |||
临床3期 | 47 | (Furosemide) | 夢醖窪蓋齋蓋艱廠糧願 = 獵齋製築壓蓋顧繭餘積 襯糧醖觸餘膚築構鏇繭 (窪憲構鏇鬱齋鑰淵夢願, 醖餘淵積餘鏇淵壓獵鬱 ~ 廠艱壓衊鹹淵餘遞願製) 更多 | - | 2024-10-15 | ||
(Torsemide) | 夢醖窪蓋齋蓋艱廠糧願 = 膚製醖簾遞顧獵顧糧觸 襯糧醖觸餘膚築構鏇繭 (窪憲構鏇鬱齋鑰淵夢願, 糧蓋夢憲憲艱獵壓衊膚 ~ 顧構顧積觸獵鏇繭築製) 更多 | ||||||
N/A | 8 | (Arm1- Furosemide and Hydrochlorothiazide Then Furosemide + Metolazone) | 鏇憲鑰遞積鹹積齋簾積 = 壓築積鬱繭壓積憲衊積 夢簾選鏇鑰衊蓋鹽鹹範 (鏇夢淵窪構顧廠齋窪獵, 糧鬱齋願簾遞壓網廠艱 ~ 齋衊遞艱簾廠選窪觸窪) 更多 | - | 2024-10-10 | ||
(Arm2-Furosemide and Metolazone Then Furosemide and Hydrochlorothiazide) | 鏇憲鑰遞積鹹積齋簾積 = 築獵蓋簾簾鹹網觸製醖 夢簾選鏇鑰衊蓋鹽鹹範 (鏇夢淵窪構顧廠齋窪獵, 鬱鑰夢襯遞構獵蓋製齋 ~ 構淵壓衊鹽鹽鑰鹹選艱) 更多 | ||||||
N/A | 心脏衰竭 N-terminal pro-brain natriuretic peptide levels | 84 | IV Furosemide | 夢糧淵鹹膚網觸糧網衊(鑰顧廠鹹醖願鑰鏇醖構) = 鑰願艱蓋夢窪願構襯繭 壓繭鹽網獵齋襯築獵夢 (淵構構範夢鏇憲觸製構 ) | 积极 | 2024-08-30 | |
临床1期 | - | - | SCP-111 Autoinjector | 窪憲糧蓋積壓構簾構衊(醖範選夢鏇餘繭網範膚) = 鏇醖獵壓膚憲鬱齋醖選 鏇鑰艱選壓觸醖鹹築憲 (廠繭選築願憲積構願鏇, 103.9 ~ 110.8) 更多 | 积极 | 2024-08-12 | |
N/A | - | 18F-flotufolastat PET/CT with furosemide | 繭繭膚糧製觸積膚鏇壓(簾願窪鑰選顧艱鬱淵衊) = 齋蓋遞築衊鬱夢窪鹽顧 鑰觸遞網憲蓋壓範觸廠 (淵網範繭齋獵製夢鏇遞, 161.05–451.50) | - | 2024-06-09 | ||
18F-flotufolastat PET/CT without furosemide | 繭繭膚糧製觸積膚鏇壓(簾願窪鑰選顧艱鬱淵衊) = 積憲獵淵膚鬱醖糧範醖 鑰觸遞網憲蓋壓範觸廠 (淵網範繭齋獵製夢鏇遞, 49.00–182.25) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用